These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26790725)

  • 1. Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents.
    Matsumoto T; Jimi S; Migita K; Takamatsu Y; Hara S
    Leuk Res; 2016 Feb; 41():103-10. PubMed ID: 26790725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells.
    Gwak H; Haegeman G; Tsang BK; Song YS
    Mol Carcinog; 2015 Dec; 54(12):1529-40. PubMed ID: 25307508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
    David E; Sinha R; Chen J; Sun SY; Kaufman JL; Lonial S
    Clin Cancer Res; 2008 Aug; 14(16):5090-8. PubMed ID: 18698026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin.
    Wang YD; Li SJ; Liao JX
    Technol Cancer Res Treat; 2013 Dec; 12(6):525-35. PubMed ID: 23617290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation.
    Zhao F; Ming J; Zhou Y; Fan L
    Cancer Chemother Pharmacol; 2016 May; 77(5):963-72. PubMed ID: 27011212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.
    Bustany S; Cahu J; Descamps G; Pellat-Deceunynck C; Sola B
    J Hematol Oncol; 2015 Apr; 8():40. PubMed ID: 25898974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
    Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
    Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
    Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
    Baumann P; Müller K; Mandl-Weber S; Leban J; Doblhofer R; Ammendola A; Baumgartner R; Oduncu F; Schmidmaier R
    Br J Haematol; 2009 Mar; 144(6):875-86. PubMed ID: 19170678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
    Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
    Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia.
    Cao X; Fang L; Gibbs S; Huang Y; Dai Z; Wen P; Zheng X; Sadee W; Sun D
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):495-505. PubMed ID: 16906425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
    Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
    Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.
    Mishra RK; Wei C; Hresko RC; Bajpai R; Heitmeier M; Matulis SM; Nooka AK; Rosen ST; Hruz PW; Schiltz GE; Shanmugam M
    J Biol Chem; 2015 Jun; 290(23):14441-53. PubMed ID: 25847249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
    Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
    Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
    Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.